近日，国家知识产权出版社发布《金融科技行业2025年专利分析白皮书》与《医疗健康行业2025年专利 分析白皮书》(以下简称"白皮书")，揭示全球产业技术竞争的新格局。白皮书显示，2019年至2025年 间，中国企业在两大战略性行业的创新主导地位愈发巩固。其中，中国平安集团凭借持续且庞大的创新 产出，在金融科技与医疗健康两大行业的全球专利人榜单中再度双双位列第一，并在多项核心技术与关 键应用场景中占据领先地位。 双榜首引领：专利规模构筑创新护城河 平安集团的创新布局呈现出"核心技术聚焦+全场景覆盖"的鲜明特征，人工智能(AI)与大数据是驱动战 略的核心技术引擎。 在金融科技专利布局中，平安集团的专利覆盖广度与规模领先全行业，在人工智能、区块链、大数据三 大技术领域的专利数量均位列第一，且相关技术已深度融入业务肌理。例如，在智能客服与保险理赔两 大场景中，人工智能成效已然显现：平安2025年前三季度报告显示，依托AI与大数据的"保单复效难度 评分模型"及智能派工体系，推动保单复效率提升23%。 表1 金融科技行业全球专利权人TOP 10 在医疗健康领域，平安集团的领先优势同样显著，同期累计专利量达到5704件，位 ...

Core Viewpoint - The insurance sector experienced a 1.1% increase on February 4, with China Pacific Insurance leading the gains, while the overall market indices also showed positive movement [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4102.2, up 0.85% [1] - The Shenzhen Component Index closed at 14156.27, up 0.21% [1] Group 2: Individual Stock Performance - China Pacific Insurance (601601) closed at 44.73, with a gain of 1.71% and a trading volume of 287,300 shares, totaling a transaction value of 1.275 billion yuan [1] - New China Life Insurance (601336) closed at 81.55, up 1.34% with a trading volume of 145,900 shares [1] - Ping An Insurance (601318) closed at 67.40, gaining 1.23% with a trading volume of 877,400 shares [1] - China Life Insurance (601628) closed at 48.70, up 0.81% with a trading volume of 147,900 shares [1] - China Reinsurance (601319) closed at 9.09, gaining 1.00% with a trading volume of 704,700 shares [1] Group 3: Capital Flow - The insurance sector saw a net inflow of 318 million yuan from institutional investors, while retail investors experienced a net outflow of 28.0153 million yuan [1] - The capital flow for major stocks showed that Ping An Insurance had a net inflow of 281 million yuan from institutional investors, but a net outflow of 265 million yuan from speculative investors [2] - China Pacific Insurance had a net inflow of approximately 36.6 million yuan from institutional investors, while retail investors saw a net outflow of about 61.9 million yuan [2]

随着人口结构变化、疾病谱系变迁以及民众对健康品质需求的不断提升，单纯以疾病治疗为中心的医疗 模式已不能满足多元化的健康需求。社会办医作为公立医疗服务体系的重要补充，在这场变革中扮演着 愈发关键的角色。其中，由保险资本主导的医疗集团，因其独特的资源禀赋与商业模式，被视为重塑产 业格局的重要变量。 北大医疗作为这一领域的先行者与代表性机构，具有双重基因：一是源自北京大学医学部逾百年的深厚 学术底蕴、严谨医风与顶尖人才体系，这是其医疗品质的压舱石；二是来自中国平安集团的综合金融资 源、科技创新能力与庞大客户生态，这是其模式创新的推进器。两种不同的基因如何真正融合？险资办 医如何平衡医疗本质与市场逻辑？在医疗健康产业变革的十字路口，北大医疗如何走出一条可持续的创 新之路？针对上述问题，近日，《金融时报》记者对北大医疗董事长、平安健康险董事长兼首席执行官 朱友刚进行了专访。 《金融时报》记者：北大医疗所实践的"保险+医疗"模式，最根本的优势与核心的挑战是什么？在实践 中，北大医疗如何用好"北大底蕴"与"平安特色"？ 朱友刚：首先谈优势。险资办医，尤其是背靠大型综合金融集团办医，核心优势在于两个方面。一是构 建"支付+服 ...

Content: --------- <doc id='1'>融资融券月报 13307 主要指数全部上涨，两融余额继续上升 ――融资融券 2 月月报</doc> <doc id='2'>| 分析师：王雪莹 | SAC NO：S1150525020001 2026 年 2 月 4 日 | | --- | --- | | 证券分析师 | 核心观点： | | 王[Table_IndInvest] 雪莹 | | | | 市场概况 | |  022-23839121 | | | wangxy4430@bhzq.com  | 本月（1 月 1 日-1 月 30 日）A 股市场主要指数全部上涨，其中科创 50 | | | 涨幅最大，上涨了 12.29%；上证 50 涨幅最小，上涨了 1.17%。此外， | | | 上证综指上涨 3.76 %，深证成指上涨 5.03%，创业板指上涨 4.47%， | | | 沪深 上涨 上涨 300 1.65 %，中证 500 12.12%。 | |  | 截至 1 月 30 日，沪深两市两融余额为 27,064.74 亿元，较上月末增加 | | | 1,737.60亿元。其中融资余额为 26,898.76 亿元，较上月末增加 1,736.88 | | | 亿元；融券余额为 165.99 亿元，较上月末增加 0.72 亿元。市场 ETF | | | 融资余额为 亿元，较上月末增加 亿元；融券余额为 1128.80 33.06 73.71 | | | 亿元，较上月末增加 亿元。户均融资融券余额为 元，较 0.94 1,414,996 | | | 上月末增加 35,599 元；有融资融券负债的投资者数量占全体融资融券 | | | 投资者数量的占比为 23.97%，较上月末增加 0.73 个百分点。1 月 1 日 | | | -1 月 30 日每日平均参与融资融券交易的投资者数量为 600,192 名，较 | | | 上月增长 42.73%。 | |  | 板块方面，主板和科创板融资余额占沪深两市 A 股融资余额比例下降， | | | 创业板占沪深两市 A 股融资余额比例上升。融券方面，主板和科创板融 | | | 券余额占沪深两市 A 股融券余额比例上升，创业板占沪深两市 A 股融券 | | | 余额比例下降。 | |  | 标的券情况 | |  | 行业方面，本月有色金属、电子和非银金融行业融资净买入额较多，建 | | | 筑材料、轻工制造和美容护理行业融资净买入额较少；本月融资买入额 | | | 占成交额比例较高的行业为非银金融、通信和电子，较低的行业为纺织 | | | 服饰、轻工制造和建筑材料；本月有色金属、食品饮料和家用电器行业 | | | 融券净卖出额较多，电力设备、电子和医药生物行业融券净卖出额较少。 | |  | 个股方面，本月个股融资净买入额前五名为中国平安（601318）、紫金 | | | 矿业（601899）、天孚通信（300394）、招商银行（600036）、长江电 | | | 力（600900）。本月个股融券净卖出额前五名为贵州茅台（600519）、 | | | 赤峰黄金（600988）、兴业银锡（000426）、美的集团（000333）、洛 | | | 阳钼业（603993）。 | |  | 风险提示：两融业务成本超预期变动风险；两融监管政策超预期变动风 | | | 险。 | | 请务必阅读正文之后的声明 | 渤海证券股份有限公司具备证券投资咨询业务资格 1 of 20 |</doc> <doc id='3'>金 融 工 程 研 究 证 券 研 究 报 告 融 资 融 券 月 报</doc> <doc id='5'>| 1. 市场数据概览 | | 4 | | --- | --- | --- | | 2. 行业融资融券特征 | | 9 | | 3. ETF 标的券 | | 13 | | 4. 个股标的券及重大事项 | | 15 | | 5. 结论 | | 17 |</doc> <doc id='6'>| | |</doc> <doc id='7'>| 图 1：近一年沪深 300 收盘价与融资买入额占成交额比例 4 | | --- | | 图 2：本月融资业务情况 5 | | 图 3：本月融券业务情况 5 | | 图 4：近五年两融余额情况 6 | | 图 5：各板块融资余额情况（亿元） 6 | | 图 6：各板块融券余额情况（亿元） 6 | | 图 7：各指数融资余额情况（亿元） 7 | | 图 8：各指数融券余额情况（亿元） 7 | | 图 9：近一年融资融券机构投资者及个人投资者数量 8 | | 图 10：近一年参与融资融券交易的投资者数量与有融资融券负债的投资者数量 8 | | 图 11：本月申万一级行业涨跌幅及融资买入额占成交额比例（%） 9 | | 图 12：本月行业融资净买入额情况（万元） 9 | | 图 13：本月行业融券净卖出额情况（万元） 10 | | 图 14：近一年 ETF 融资融券余额情况 13 | </doc> <doc id='8'>| 表 1：A | 股市场主要指数本月表现 4 | | --- | --- | | 表 2：本月标的券所属行业融资情况 10 | | | 表 3：本月标的券所属行业融券情况 11 | | | 表 4：本月 ETF 融资净买入前 20 | 名 13 | | 表 5：本月个股融资净买入前 20 | 名 15 | | 表 6：本月融资买入额占成交额比例前 | 20 名 15 | | 表 7：本月个股融券净卖出前 20 | 名 16 |</doc> <doc id='9'>1. 市场数据概览 本月（1 月 1 日-1 月 30 日）A 股市场主要指数全部上涨，其中科创 50 涨幅最大， 上涨了 12.29%；上证 50 涨幅最小，上涨了 1.17%。此外，上证综指上涨 3.76 %， 深证成指上涨 5.03%，创业板指上涨 4.47%，沪深 300 上涨 1.65 %，中证 500 上涨 12.12%。</doc> <doc id='10'>表 1：A 股市场主要指数本月表现 | 指数名称 | 12 月 31 日收盘价 | 1 月 30 日收盘价 | 月涨跌幅(%) | | --- | --- | --- | --- | | 上证综指 | 3968.84 | 4117.95 | 3.76 | | 深证成指 | 13525.02 | 14205.89 | 5.03 | | 创业板指 | 3203.17 | 3346.36 | 4.47 | | 科创 50 | 1344.20 | 1509.40 | 12.29 | | 沪深 300 | 4629.94 | 4706.34 | 1.65 | | 上证 50 | 3031.13 | 3066.50 | 1.17 | | 中证 500 | 7465.57 | 8370.52 | 12.12 | 资料来源：同花顺，渤海证券研究所 图 1：近一年沪深 300 收盘价与融资买入额占成交额比例</doc> <doc id='12'>资料来源：同花顺，渤海证券研究所 1 月 30 日，沪深两市两融余额为 27,064.74 亿元，较上月末增加 1,737.

随着人口结构变化、疾病谱系变迁以及民众对健康品质需求的不断提升，单纯以疾病治疗为中心的 医疗模式已不能满足多元化的健康需求。社会办医作为公立医疗服务体系的重要补充，在这场变革中扮 演着愈发关键的角色。其中，由保险资本主导的医疗集团，因其独特的资源禀赋与商业模式，被视为重 塑产业格局的重要变量。 北大医疗作为这一领域的先行者与代表性机构，具有双重基因：一是源自北京大学医学部逾百年的 深厚学术底蕴、严谨医风与顶尖人才体系，这是其医疗品质的压舱石；二是来自中国平安集团的综合金 融资源、科技创新能力与庞大客户生态，这是其模式创新的推进器。两种不同的基因如何真正融合？险 资办医如何平衡医疗本质与市场逻辑？在医疗健康产业变革的十字路口，北大医疗如何走出一条可持续 的创新之路？针对上述问题，近日，《金融时报》记者对北大医疗董事长、平安健康险董事长兼首席执 行官朱友刚进行了专访。 《金融时报》记者：北大医疗所实践的"保险+医疗"模式，最根本的优势与核心的挑战是什么？在 实践中，北大医疗如何用好"北大底蕴"与"平安特色"？ 朱友刚：首先谈优势。险资办医，尤其是背靠大型综合金融集团办医，核心优势在于两个方面。一 是构建"支付+服 ...

- The report introduces a quantitative model framework for market trend analysis, focusing on five asset style stages: external growth, quality growth, quality dividend, value dividend, and bankruptcy value. The model evaluates assets based on their intrinsic attributes and prioritizes them using the sequence of g > ROE > D, analyzing whether there are "good assets" and whether they are "expensive" [5][8][9] - The model incorporates key factors such as expected growth (gf), actual growth (g), profitability (ROE), high dividend (D), and bankruptcy value (B/P). Each factor is associated with specific market phases, e.g., expected growth is relevant across all phases, while profitability is emphasized during maturity phases [9][12] - The quantitative model has demonstrated strong historical performance, achieving an annualized return of 27.67% since 2009. It has shown consistent excess returns in most years, particularly post-2017, with limited effectiveness in years like 2011, 2012, and 2016 [19][22] - The model's backtesting results for specific years include notable excess returns, such as 51% in 2009, 36% in 2013, and 62% in 2022. However, it also recorded underperformance in years like 2011 (-11%) and 2014 (-4%) [22] - The report details six specific strategies derived from the model, each focusing on different factors: - **Expected Growth Strategy**: Selects industries with the highest analyst-forecasted growth rates. Recent recommendations include sectors like automotive sales, lithium equipment, and tungsten [38][39] - **Actual Growth Strategy**: Focuses on industries with the highest unexpected growth (△g). Current recommendations include photovoltaic equipment, insurance, and coal chemical sectors [40][41] - **Profitability Strategy**: Targets high-ROE industries with low valuations under the PB-ROE framework. Recommended sectors include copper, liquor, and non-dairy beverages [43][44] - **Quality Dividend Strategy**: Utilizes a DP+ROE scoring system to identify industries. Current recommendations include forestry, lithium equipment, and fiberglass [46][47] - **Value Dividend Strategy**: Employs a DP+BP scoring system. Recommended sectors include security, daily chemicals, and buses [49][50] - **Bankruptcy Value Strategy**: Focuses on industries with the lowest PB+SIZE scores. Current recommendations include automotive sales, ceramics, and cotton textiles [53][54]

二、中国平安财产保险股份有限公司应按照有关规定及时办理变更及许可证换领事宜。 一、同意中国平安财产保险股份有限公司成安支公司将营业场所变更为：河北省邯郸市成安县青云大街 西侧、朱雀路北侧业玖大厦B座12层1201、1212。 2026年1月27日，邯郸金融监管分局发布批复称，《中国平安财产保险股份有限公司河北分公司关于变 更平安财险成安支公司营业场所的请示》(平保产冀分发〔2025〕165号)收悉。经审核，现批复如下： ...

Group 1 - The core point of the article highlights the performance of the HuShen 300 Growth ETF managed by Huaxia Fund Management, which has seen a return of 28.50% since its inception on September 5, 2023, and a return of 3.61% over the past month [1][1][1] - As of the midday close on February 4, the HuShen 300 Growth ETF (159523) decreased by 0.31%, with a trading volume of 2.2597 million yuan [1][1][1] - The top holdings of the ETF include companies such as CATL, which rose by 1.58%, Kweichow Moutai, which increased by 2.01%, and Zijin Mining, which saw a slight increase of 0.05% [1][1][1] Group 2 - Other notable stock performances within the ETF include Sunlight Power, which fell by 0.27%, Haiguang Information, which dropped by 3.51%, and Heng Rui Pharmaceutical, which decreased by 2.14% [1][1][1] - The ETF's performance benchmark is the CSI Select 300 Growth Innovation Strategy Index return rate [1][1][1] - The fund manager is Zhao Zongting, indicating a specific leadership in the management of the ETF [1][1][1]

智能预警联动救援,小保单托举大民生 御享金越年金的核心竞争力源于其背后的投资体系,产品依托平安人寿专为分红险打造的"稳赢宝"账户, 执行"三仓"配置策略:长期战略仓锁定穿越周期的底层收益,中期情境仓灵活应对市场风格切换,短期战术 仓捕捉波段机会。这一机制直接体现在业绩上,中国平安2025年三季度财报显示,其保险资金投资组合实 现非年化综合投资收益率5.4%。凭借优异的综合投资实力,平安人寿在南方周末"金标杆-寿险投资能力 榜"中位列万亿级险企之首。产品设计上,御享金越年金在交费期满一定年度后,现金价值持续增长,保单 持有人还可参与分配分红业务70%以上的可分配盈余,红利亦能转入万能账户实现二次增值。 日前,"完善服务体系 赋能科技生活"2025第七届上海普惠金融论坛在中国金融信息中心举行。会议聚焦 普惠金融治理体系完善与服务质效提升,探讨金融机构如何通过数字化转型破解融资难题、赋能科技产 业。在此背景下,平安人寿推出的御享金越年金凭借其稳健的分红机制与综合服务能力,备受关注。该产 品精准响应上海金融监管局关于2030年实现普惠金融服务能力跃升的规划,以供给侧改革为切入点,为客 户提供了穿越经济周期的财富管理方 ...

Investment Rating - The industry investment rating is "Recommended" for the insurance sector, indicating an expected increase in the industry index exceeding the benchmark index by more than 5% in the next 3-6 months [4][24]. Core Insights - The insurance industry achieved a total premium income of 61,194 billion yuan in 2025, reflecting a year-on-year growth of 7.4%. The growth rate has slightly decreased compared to the previous month [7][6]. - Life insurance premiums reached 35,557 billion yuan, with a year-on-year increase of 11.4%. Health and accident insurance also showed growth, while the overall premium growth rate for life insurance has been gradually declining [7][6]. - The total assets of the insurance industry reached 41.3 trillion yuan by the end of December 2025, marking a year-on-year increase of 15.1% [7][6]. - The report anticipates that the new business for life insurance will see rapid growth due to the dual benefits of high deposit flow and the expansion of bank insurance channels [7][6]. Company Summaries - **China Pacific Insurance (601601.SH)**: Expected EPS for 2025E is 5.68 yuan, with a PE ratio of 7.21 and a PB ratio of 1.41. The stock is rated as "Recommended" [3]. - **China Life Insurance (601628.SH)**: Expected EPS for 2025E is 6.34 yuan, with a PE ratio of 11.79 and a PB ratio of 2.18. The stock is rated as "Recommended" [3]. - **Ping An Insurance (601318.SH)**: Expected EPS for 2025E is 8.02 yuan, with a PE ratio of 7.48 and a PB ratio of 1.14. The stock is rated as "Strongly Recommended" [3]. - **China Property & Casualty Insurance (02328.HK)**: Expected EPS for 2025E is 2.07 yuan, with a PE ratio of 6.54 and a PB ratio of 1.09. The stock is rated as "Recommended" [3].